XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd.

4.0 12 Reviews
Haven't used XTL Biopharmaceuticals Ltd. yet?
Ask AI

Ask AI about XTL Biopharmaceuticals Ltd.

Generated with AI from 12 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Rob Muir
Reviews 1

I have been a loyal customer of XTL Biopharmaceuticals Ltd. for many years now and I have never been disappointed. The quality of their products is always top-notch and the customer service is excellent. I would highly recommend them to anyone!

Mahmudul Hasan
Reviews 1

I have been using XTL Biopharmaceuticals Ltd.'s products for several years now and I must say, their quality is consistently amazing. The level of service provided by the company is top-notch and I am always satisfied with my orders. Highly recommended!

Kate Price
Reviews 1

I have been using various products from xtlbio.com for quite some time now and I am extremely satisfied with the quality. The customer service is also excellent and they always respond promptly to any inquiries or concerns. Highly recommend!

Questions & Answers

No questions yet — be the first to ask.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="xtlbio-com" data-lang="en"></div>
More widgets

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus.

The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals.

Website
xtlbio.com